Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?—a systematic review and meta-analysis

Overview of attention for article published in Supportive Care in Cancer, August 2017

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 6,651 followers.

RT @FarmaOnco: Is addition of NK1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a review & meta-analysis. https://t…

Añadir antagonistas NK1 en esquemas de carboplatino: beneficios clínicamente significativos contra la emetogenicidad https://t.co/5yqnvvOax8

Is addition of NK1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a review & meta-analysis. https://t.co/HpM1wZGdFP

RT @FlorianSlimano: Systematic Review and meta-analyse: #aprepitant is beneficial in Moderate Emetog chemo only if #carboplatine-based http…

RT @FlorianSlimano: Systematic Review and meta-analyse: #aprepitant is beneficial in Moderate Emetog chemo only if #carboplatine-based http…

Systematic Review and meta-analyse: #aprepitant is beneficial in Moderate Emetog chemo only if #carboplatine-based https://t.co/sHpyDZ2R6r